Anti-ID Ab Development Service
Specializing in Anti-Idiotype Antibodies for Cell Therapy
CytoArt is deeply committed to advancing cell therapy and has launched the world’s first commercialized anti-idiotype antibody. We have supported over 200 companies globally—including 5 of the top 20 pharmaceutical companies—supporting from early research and preclinical studies to clinical development and commercialization. Our anti-idiotype antibodies cover six FDA-approved CAR-T therapies.
With extensive experience in antibody development, we design antibodies tailored to clients’ specific sequences. Leveraging our robust screening and validation platforms, we deliver high-sensitivity, high-specificity, and low-background antibodies.
Why Choose CytoArt?
Advanced Platform
Powered by our proprietary CAR-Drive platform and multiple patented technologies, we offer customized monoclonal antibodies, multi-specific antibodies, and ADA detection kits.
Extensive Experience
Over 8 years of experience in anti-idiotype antibody development, covering the broadest range of targets from FDA-approved CAR-T therapies.
Rapid Delivery
Delivery starting from 20 weeks (timelines may vary depending on antigen characteristics, antibody format, and application requirements).
Global Reach
Serving clients across the United States, China, Europe, Japan, South America, and Southeast Asia.
Ready to Customize Your Antibody?
CAR-Positive Detection
CAR-positive detection is essential across the CAR-T lifecycle, supporting quality control in manufacturing and pharmacokinetic monitoring of CAR-T cell expansion and persistence in preclinical and clinical studies. CytoArt provides custom anti-idiotype antibodies with high sensitivity, high specificity, and low background, enabling precise and reliable CAR-positive detection to meet customers’ diverse needs.
Immunogenicity Evaluation
CytoArt offers comprehensive anti-drug antibody (ADA) detection solutions for CAR-T therapies, including ELISA kits and positive control antibodies. We deliver complete ADA detection solutions and enable cell line-based testing to support various stages of development. Our CAR immunogenicity ELISA kit achieves an ultra-low LOD of 0.31 ng/mL, ensuring the highest sensitivity for detecting ADA. Powered by anti-idiotype antibody strategies, our assays deliver high specificity, strong reproducibility, and reliable data to support both preclinical and clinical development.
Development Process
CytoArt provides specialized anti-idiotype antibody development to support CAR-T cell detection and immunogenicity assessment. Our antibodies enable accurate and sensitive measurement of CAR-T positivity, with additional applications in ADA detection. We deliver high-affinity, highly specific antibodies tailored to your CAR constructs, supported by flexible, end-to-end solutions from design to validation.
1. Immunogen & Positive Cell Line Preparation
2. Immunization & Serum Titer Test
3. Phage Display Library Construction, Panning & Screening
4. Small-Scale Antibody Expression & Validation
5. Detection Antibody Delivery